FDA approval for new once-daily HIV treatment Symfi™

The global pharmaceutical company Mylan N.V. (PA, USA) has received FDA approval for Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) – a once-daily, single-tablet regimen, which is appropriate for HIV-1 infection in adult and pediatric patients weighing at least 40 kg.
To view restricted content, please:

Leave A Comment